business
COMPANY BENCHMARKING • UNITED STATES

Eli Lilly And Company - Company Profile

Access all 5,000+ company profiles through Benchmarking Pro, available to Membership Plus subscribers. Unlock interactive competitor comparison tools that show you how Eli Lilly And Company stacks up to the competition and put relevant competitor and industry information at your fingertips.


Eli Lilly And Company - Overview

Brands
Alimta, Byetta, Cialis, Cymbalta, Darvocet, E-Mycin, Effient, Evista, Forteo, Gemzar, Glucagon, Humatrope, Humulin, Methadone, Prozac, ReoPro, Secobarbital, Strattera, Symbyax, Thimerosal, Xigris, Zyprexa
Description
Eli Lilly And Company is a public company headquartered in Indiana with an estimated 38,350 employees. In the US, the company has a notable market share in at least two industries: Brand Name Pharmaceutical Manufacturing and ADHD Medication Manufacturing. Their largest market share is in the Brand Name Pharmaceutical Manufacturing industry, where they account for an estimated 2.8% of total industry revenue and are considered a Golden Goose because they display medium to strong market share and strong profit, but slower revenue growth than some of their peers.
Company Details

Registered Name: Eli Lilly And Company

Company Type: Operating

Exchange: NYSE

Headquarters: Lilly Corporate Center Drop Code 1094 Indianapolis IN 46285

Website: http://www.lilly.com/

Employees: 38350

Eli Lilly And Company - Operating Industries and Main Competitors

error_outline To view all of Eli Lilly And Company's operating industries and competitors, see purchase options.

Eli Lilly And Company - Products and Services

error_outline To view Eli Lilly And Company's full products and services, see purchase options.

Eli Lilly And Company - Analyst Insights

Eli Lilly and Company sees growth in 2021

On February 3, 2022, Eli Lilly and Company (Lilly) reported its 2021 financial earnings where the company has earned $28.3 million in the year, which is a 15% increase from last year's revenue. Various products that the company has produced from Trulicity, Taltz, and Verzenio have been estimated to have contributed 14% of the growth in revenue for the year. 2021 was also a year of change in the company with various assets undergoing restructuring and impairment along with the company incurring more costs from research and development.

Discontinued Activity


In response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.

Lorem Ipsum text header Report Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.

error_outline To view all analyst insights on Eli Lilly And Company, see purchase options.

Eli Lilly And Company - SWOT Analysis

Strengths and weaknesses take into account internal factors, and are based on Eli Lilly And Company's performance in comparison to its competitors. Opportunities and Threats focus on external influences, and are based on trends and demand in the Brand Name Pharmaceutical Manufacturing in the US industry.
Strengths
Days Receivables: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Annual Turnover: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Weaknesses
Credit Risk: x.x%
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Revenue per Employee: $xx
Purchase a membership to unlock the full SWOT analysis of this company.
lock
Rank: 2 of 3 peers
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Opportunities
  • AAAAA
  • AAAAA
  • AAAAA
Threats
  • AAAAA
  • AAAAA
  • AAAAA

error_outline To view Eli Lilly And Company's full SWOT analysis, see purchase options.

Eli Lilly And Company - Financial Statements & Ratios

pie_chartEli Lilly And Company Income Statement

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Revenue28,318.424,539.822,319.521,493.319,973.818,312.8
Cost of Revenue000000000000000000000000
Cost of Revenue, Non-Cash000000000000000000000000
Gross Profit000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

pie_chartEli Lilly And Company Balance Sheet

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Cash and Equivalents3,818.53,657.12,337.57,320.76,211.84,582.1
Short-Term Investments000000000000000000000000
Derivative Assets, Current000000000000000000000000
Restricted Cash and Investments000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

pie_chartEli Lilly And Company Cash Flow

BALANCE DATE12/31/202112/31/202012/31/201912/31/201812/31/201712/31/2016
Net IncomeN/AN/AN/AN/AN/AN/A
Income (Loss) From Discontinued Operations000000000000000000000000
Depreciation, Depletion and Amortization000000000000000000000000
Amortization of Financing Costs and Discounts000000000000000000000000
AAAAAA AAAAAA000000000000000000000000

error_outline To view Eli Lilly And Company's full competitive environment, see purchase options.

GET INSTANT ACCESS WITH MEMBERSHIP PLUS

100% Money Back Guarantee Digicert Trusted

BENCHMARKING PRO

What's Inside
Benchmarking Pro?

Available with US Membership Plus packages, this suite of company and industry data:

Benchmarks companies against industry averages or like-sized segments, as well as close competitors
Identifies real-world strengths, opportunites, weaknesses and threats
Reveals growth opportunities or red flags in a business growth strategy

Included in Report

  • Enterprise History & Synopsis
    Enterprise History & Synopsis
  • Enterprise Financial Statements
    Company Financial Statements
  • Financial Ratios
    Industry Market Share Breakdown
  • Industry Averages
    Industry Competitor Matrix
  • Competitive Landscape
    SWOT Analysis
  • Key Enterprise Personnel
    Products and Services
  • Subsidiaries & Ownership Structure
    Key Company Benchmarks

Why purchase access to Benchmarking Pro?

This profile on Eli Lilly And Company includes:

  • Company Overview
  • Company Revenue and Employee Data
  • Company Financial Statements
  • Industry Market Share Breakdown
  • Industry Competitor Matrix
  • SWOT Analysis
  • Products and Services
  • Key Company Benchmarks
  • Interconnected Competitor Profiles and Industry Reports
  • Full Access to Benchmarking Pro

The IBISWorld Benchmarking Pro solution enables you to:

  • Understand a enterprise’s competitive landscape and how they perform within a like-sized industry segment.
  • Benchmark companies against industry averages, segment averages and their competitors.
  • Identify real-world strengths, opportunities, weaknesses and threats for companies.
  • Target growth opportunities or spot red flags in a business growth strategy.
  • Toggle between company profiles and industry reports for a 360 degree view of a company's position.

IBISWorld provides profiles on thousands of leading companies around the world. Our clients rely on our information and data to stay up-to-date on business and industry trends across all sectors of the economy. This company profile, along with the corresponding competitor and industry data provided, includes thoroughly researched, reliable and current information that will help you to make faster, better business decisions.

Trusted by More Than 10,000 Clients Around the World

  • IBISWorld client - VISA
  • IBISWorld client - ADP
  • IBISWorld client - Deloitte
  • IBISWorld client - AMEX
  • IBISWorld client - Bank of Montreal